Core Insights - Kura Oncology, Inc. is hosting two virtual investor and analyst events to showcase its farnesyl transferase inhibitor (FTI) program, emphasizing its leadership in targeting cancer signaling pathways for solid tumors and hematologic malignancies [1][5] Event Summaries - The first event on September 16, 2025, will focus on the preclinical program of FTIs, discussing their synergistic combinations with targeted therapies such as tyrosine kinase inhibitors, RAS inhibitors, and PI3K alpha inhibitors, highlighting their potential to transform treatment for solid tumors [2] - The second event on October 18, 2025, will present clinical data from the 2025 ESMO Congress, including the first clinical insights from KO-2806, Kura's next-generation FTI, which aims to address resistance mechanisms in cancer [3] ESMO Congress Presentations - Kura will present preliminary results from the FIT-001 phase 1 trial of KO-2806 in combination with cabozantinib for renal cell carcinoma on October 18, 2025 [4] - A phase 1 study of KO-2806 as monotherapy in advanced solid tumors will be presented on October 19, 2025 [4] - Results from the KURRENT-HN trial involving tipifarnib and alpelisib in recurrent/metastatic head and neck squamous cell carcinoma will be shared on October 20, 2025 [4] Company Overview - Kura Oncology is a clinical-stage biopharmaceutical company focused on precision medicines for cancer, with a pipeline targeting cancer signaling pathways and addressing high-need hematologic malignancies and solid tumors [5] - The company is developing ziftomenib, a menin inhibitor for acute myeloid leukemias, and is advancing both menin and farnesyl transferase inhibition strategies to tackle resistance mechanisms in solid tumors [5][6]

Ziftomenib Development and Clinical Trials - Ziftomenib is a targeted menin inhibitor being developed for relapsed/refractory and newly diagnosed acute myeloid leukemia (AML)[7] - An NDA for ziftomenib has been granted Priority Review, with a PDUFA target action date of November 30, 2025[7] - Kura Oncology and Kyowa Kirin are collaborating to investigate ziftomenib across the AML continuum, targeting up to 50% of patients for whom the Menin-KMT2A pathway is a disease driver[59] - KOMET-017 are Phase 3 clinical trials evaluating ziftomenib in combination with intensive chemotherapy (7+3) or non-intensive therapy (Venetoclax + Azacitidine) in newly diagnosed AML patients[62] KOMET-007 Clinical Trial Results - In the KOMET-007 study, the combination of ziftomenib 600 mg QD with 7+3 chemotherapy showed a safety profile consistent with previous reports for newly diagnosed AML patients treated with 7+3 alone[56] - The KOMET-007 study demonstrated robust clinical activity in newly diagnosed NPM1-m and KMT2A-r AML patients, with a composite complete remission (CRc) rate of 93% for NPM1-m and 89% for KMT2A-r patients[56] - Composite complete remission with measurable residual disease (CRc MRD) negativity was achieved in 68% of NPM1-m patients at a median of 4.7 weeks and 83% of KMT2A-r patients at a median of 4.1 weeks[56] - 96% (47/49) of NPM1-m and 88% (29/33) of KMT2A-r patients remained alive and continued on-study, with median follow-up times of 25 and 16 weeks, respectively[56] AML Market and Opportunity - An estimated 22,000 new cases of AML are diagnosed each year in the United States[16] - Up to 50% of AML cases may be menin-dependent, including those driven by NPM1m and KMT2Ar mutations[19] - The potential peak sales for menin inhibitors in first-line AML is estimated to be greater than $7 billion per year in the U.S[73]